Connect with us

Press Release

Nicholas Mirisis: The Proven Vertical SaaS CEO Redefining Growth, Discipline, and Innovation

Published

on

OH, US, 14th November 2025, ZEX PR WIRE, In today’s high-velocity digital economy, leadership in vertical SaaS demands more than a vision; it requires precision, endurance, and the ability to create sustainable value across complex ecosystems. Few leaders embody that balance as fully as Nicholas Mirisis, a proven CEO known for his ability to transform software businesses into disciplined, profitable, and high-performing market leaders.

With over two decades of experience across diverse technology verticals including EdTech, FinTech, GovTech, Healthcare, Defense Tech, and eCommerce, Mirisis has built a track record defined by strategic clarity, operational excellence, and measurable success. His leadership approach combines entrepreneurial creativity with a data-driven focus, helping organizations evolve from reactive to resilient, from struggling to scaling.

Transforming a SaaS Turnaround into a Growth Powerhouse

As the Chief Executive Officer of a leading EdTech SaaS company headquartered in Columbus, Ohio, Mirisis inherited a business facing negative growth, high operational costs, and declining morale. Within just two years, he engineered one of the most remarkable turnarounds in the company’s history.

By focusing on profitability over vanity metrics, he transformed the business into a greater than Rule of 35 performer with more than$11million in EBITDA, reversing years of losses. Under his leadership, the company streamlined its go-to-market operations, redefined pricing strategies, and embedded artificial intelligence (AI) and machine learning (ML) technologies into its core offerings, decisions that drove both customer value and enterprise efficiency.

Mirisis also restructured key revenue partnerships, renegotiating long-term contracts with state governing bodies across major athletic markets such as Texas, Ohio, and New Jersey. This move protected nearly 60% of top-line revenue and cemented the company’s role as the leading event management platform for high school athletics.

“We focused on profitable growth” Mirisis explains. “Our laser focus was quality core unit economics, operational maturity, and strategic innovation that aligns with our mission and strengthens the value we deliver to customers.”

Innovation Beyond the Balance Sheet

Nicholas Mirisis’ leadership style stands out for its dual focus on innovation and discipline, two principles often at odds in fast-scaling SaaS environments. He believes great companies are built when creativity and accountability coexist.

This mindset was evident when he spearheaded the acquisition of Schoolfundr, a fee-free fundraising software tool that expanded his company’s total addressable market by nearly $5 billion. Within a year, that division experienced 92% year-over-year growth, validating his approach of blending strategic M&A with organic innovation.

Mirisis also launched Hometown Engage, a social and communications suite designed to enhance customer retention and user engagement. The product not only elevated the brand’s positioning in the market but also contributed to an 8% increase in net revenue retention.

Through each strategic decision, Mirisis has demonstrated that innovation is not about chasing trends; it is about anticipating customer needs, creating long-term value, and ensuring operational scalability.

Building Cultures That Win

Behind every great company lies a great culture, and Mirisis has made cultural transformation a hallmark of his leadership. When he took the helm at his current company, employee morale was low and turnover was high. Within two years, he reversed the company’s employee Net Promoter Score (eNPS) from -39 to +42, a testament to his belief that high performance begins with psychological safety, clarity, and purpose.

He implemented a performance-based culture centered on merit, measurable outcomes, and continuous feedback. Mirisis also re-invested in infrastructure and systems, ensuring teams had the tools and data visibility to succeed. The result was not just happier employees but measurable business resilience, culminating in 12 minutes of downtime across the entire year and a 90% gross revenue retention rate.

“Culture isn’t about slogans; it’s about consistency,” Mirisis says. “It’s how people show up, solve problems, and celebrate progress. My job as CEO is to make excellence a habit, not a goal.”

Proven Track Record of SaaS Growth and Value Creation

Before his current role, Nicholas Mirisis played a pivotal part in scaling and selling several high-growth SaaS businesses. At Dude Solutions, he led transformative marketing and growth initiatives that helped take the company from $1 million to over $110 million in ARR, culminating in a $1.57 billion acquisition by Siemens at a 10x ARR multiple.

At GoCanvas, he served as Chief Revenue Officer, driving double-digit growth across North America, EMEA, and APAC. His leadership was instrumental in doubling company ARR and securing a strategic acquisition by Nemetschek at an 11.5x multiple, one of the highest valuations in its category.

As President at SamCart, Mirisis guided the company through a major Series B round and achieved 82% year-over-year ARR growth, helping the business scale from early-stage to enterprise-grade within two years.

Across every organization, one theme is constant: his ability to blend data-driven operational rigor with customer-centric innovation, resulting in outsized returns and sustainable growth trajectories.

A Global Perspective with Local Impact

Nicholas Mirisis’ influence extends beyond boardrooms and balance sheets. Having worked across North America, EMEA, and APAC, he has built and led global teams that thrive in diverse markets and economic conditions. His leadership philosophy emphasizes adaptability, respect for cultural context, and the ability to unify people around shared goals.

Outside his corporate roles, Mirisis serves as an advisor and board member to multiple technology-driven organizations, including Coursedog and Reveal Mobile. He also contributed his expertise to national education and technology associations, including the National Business Officers Association and the Consortium for School Networking.

An alumnus of Johns Hopkins University, where he earned a Master’s in Government, and North Carolina State University, where he received his Bachelor’s in Political Science, Mirisis combines his academic grounding with real-world pragmatism. His thought leadership bridges the gap between business strategy and human impact, a combination that continues to shape the future of SaaS.

The DNA of a Proven Vertical SaaS CEO

What sets Nicholas Mirisis apart from other leaders in the SaaS space is his ability to create order from chaos and build systems that scale. He thrives at the intersection of strategy, technology, and culture, where the toughest challenges often reside.

He views vertical SaaS as the next frontier for enterprise value creation, citing its ability to solve industry-specific problems with precision and measurable ROI. “Horizontal SaaS has had its run,” he says. “The future belongs to vertical SaaS companies that understand their industries deeply and can deliver end-to-end value with speed, security, and intelligence.”

Under his leadership, vertical SaaS companies don’t just survive; they outperform. His record speaks volumes: multiple 10x+ exits, hundreds of millions in enterprise value creation, and thousands of customers served across continents.

A Vision for the Future

Looking ahead, Nicholas Mirisis is focused on scaling the next generation of vertical SaaS companies that combine AI-driven intelligence, customer-centric design, and operational excellence. His mission is simple yet powerful: to build enduring software companies that not only deliver financial returns but also elevate the industries and communities they serve.

In a business world obsessed with speed, Mirisis champions sustainability. In an age of disruption, he preaches discipline. And in a culture of noise, he continues to lead with clarity, conviction, and integrity.

As one of the most proven vertical SaaS CEOs of his generation, Nicholas Mirisis is not just building companies; he is redefining what it means to lead them.

Contact

https://www.linkedin.com/in/nicholasmirisis/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders

Published

on

Dubai, United Arab Emirates, 13th Mar 2026 – ForexBrokers.Live is changing the way traders approach MetaTrader 4 (MT4) and MetaTrader 5 (MT5) platforms. The platform provides forex traders with essential tools, expert insights, and comprehensive guides to make informed decisions when choosing between these popular trading platforms.

MT4 has long been the go-to platform for forex traders, valued for its simplicity and reliability. Meanwhile, MT5 takes trading to the next level, offering additional features for more advanced traders, such as access to a wider range of financial instruments and enhanced charting capabilities. ForexBrokers.Live is committed to helping traders understand these platforms and how they can be used to maximize success in the forex market.

Empowering Traders with Knowledge

ForexBrokers.Live provides easy-to-understand guides that break down the complexities of both MT4 and MT5. The platform doesn’t just explain how to download and set up these platforms, it also offers expert reviews, broker comparisons, and practical tips on using advanced tools effectively. Whether you’re a beginner or an experienced trader, ForexBrokers.Live ensures you have the resources to choose the right broker and platform.

Choosing the Right Broker

Selecting the right broker is as important as choosing the right platform. ForexBrokers.Live makes this process easier by comparing brokers that support MT4 and MT5, highlighting their unique features, spreads, execution speeds, and customer support. This helps traders find the best-suited broker for their needs.

The platform goes beyond platform usage to offer in-depth broker reviews, ensuring traders are well-equipped to navigate the forex market confidently. ForexBrokers.Live also regularly updates its content, so users always have the latest information on brokers and platform features.

Looking Forward

ForexBrokers.Live continues to evolve to meet the growing needs of the trading community. The platform plans to expand its content with more detailed guides, updated reviews, and new features designed to keep traders informed and ready for the market’s challenges.

About ForexBrokers.Live

ForexBrokers.Live is a dedicated resource for forex traders, offering comprehensive guides, expert reviews, and broker comparisons for MetaTrader 4 (MT4) and MetaTrader 5 (MT5). With a focus on clarity and practicality, ForexBrokers.Live helps traders of all levels make informed decisions and choose the best platforms and brokers for their needs.

Media Contact

Organization: ForexBrokers.Live

Contact Person: Manish

Website: https://forexbrokers.live

Email: Send Email

City: Dubai

Country:United Arab Emirates

Release id:42570

The post ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC

Published

on

Export, PA, United States, 13th Mar 2026 – The upcoming episode of Now We Know! with Steve Guttenberg, airing March 14, 2026 at 1pm ET on CNBC will feature FS-Elliott, a company specializing in the design and manufacturing of high-performance centrifugal air and gas compressors.

The segment provides viewers with a behind-the-scenes look at the engineering and precision required to produce industrial equipment that supports manufacturing, energy production, and critical infrastructure worldwide. Through advanced technology and meticulous design, FS-Elliott’s compressors help power operations across a wide range of industries.

From reliability and efficiency to long-term performance, the episode highlights the role that specialized equipment plays in keeping industrial systems running smoothly.

By showcasing FS-Elliott’s work, Now We Know! sheds light on the often-unseen technologies that support modern industry. The series continues its mission to reveal the innovation and expertise behind the systems that drive everyday life.

About Now We Know!

Hosted by actor, author, and businessman, Steve Guttenberg, this unique platform inspires the next generation of knowledge seekers and viewers around the country. Each episode features up to four industry experts who provide their own unique perspective on the topic at hand via a 6-8–minute segment produced by our team, bringing a fresh look at interesting narratives, moderated by the one and only Steve Guttenberg. 

Learn more at NowWeKnowTV.com

About FS-Elliott Co., LLC

FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air and gas compressors, with operations in over 90 countries. For over 60 years, FS-Elliott has combined a commitment to quality with advanced technology, enabling our customers to increase productivity and lower system operating costs. For more information, visit www.fs-elliott.com.

For more details, contact:

Now We Know! with Steve Guttenberg

(877) 546-9995

feature@nowweknowtv.com

nowweknowtv.com

SOURCE Now We Know! with Steve Guttenberg

All images courtesy of Now We Know! with Steve Guttenberg

 

Media Contact

Organization: Now We Know!with Steve Guttenberg

Contact Person: Media Relations

Website: https://nowweknowtv.com/

Email: Send Email

Contact Number: +18775469995

City: Export

State: PA

Country:United States

Release id:42579

The post FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST